A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus

Trial Profile

A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 23 Jun 2017 Status changed from active, no longer recruiting to discontinued.
    • 30 May 2017 Planned End Date changed from 1 May 2017 to 28 Feb 2019.
    • 30 May 2017 Planned primary completion date changed from 1 Apr 2017 to 27 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top